There were lots of questions for Emergent BioSolutions CEO Robert Kramer after the troubled COVID-19 vaccine maker disclosed first-quarter earnings on Thursday after...

Even as more cell therapies push past the finish line, questions about how to make the personalized medicines swiftly and dependably persist. For Bristol M...

In 2020, Indivior resolved the federal government's long-running probe into its aggressive marketing of the opioid addiction therapy Suboxone, reaching a $600 m...

Not only do corporations have to determine when to bring employees back into the office after more than a year of at-home work, but how. It’s a decision even major C...

What's the hottest new catchphrase on TV? Monoclonal antibodies. Well, maybe not yet, but the phrase is the star of Regeneron's new TV ad campaign. In one of four ...

Queen’s “Under Pressure” would have been an appropriate soundtrack for Amgen’s earnings call on Tuesday.  Several of the California drugmaker's products are u...

People with irritable bowel syndrome (IBS) have been hurting—literally—through the pandemic. One-third of IBS patients reported worsening physical symptoms, but even...

BeiGene’s argument for its BTK inhibitor Brukinsa is that it’s a better drug than AbbVie and Johnson & Johnson’s first-to-market Imbruvica in terms of both effic...

A little over a year after Evotec's U.S. subsidiary started work on its biologics "facility of the future" in Washington, the German biotech-CRO hybrid has unveiled ...

New manufacturing workers can get acquainted with the equipment and procedures at Pfizer’s upcoming sterile injectables plant without ever setting foot inside. ...